Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1Classical hematology 1Breast 1

Conditions

Breast Neoplasms 1

Interventions

Paclitaxel 161Fulvestrant 155Trastuzumab 152pembrolizumab 144Letrozole 136Carboplatin 118pertuzumab 104Cyclophosphamide 102Capecitabine 102Specimen Handling 101Anastrozole 90palbociclib 85abemaciclib 81Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 73trastuzumab deruxtecan 69Radiotherapy 61Biopsy 59Surveys and Questionnaires 56Gemcitabine 52130-nm albumin-bound paclitaxel 52sacituzumab govitecan 50olaparib 50Standard of Care 49Blood Specimen Collection 49Taxes 47Doxorubicin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Long-Term Synaptic Depression × Breast × 1 year × Clear all
NCT07187752 2025-09-23

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

Shandong Cancer Hospital and Institute

Phase NA Not yet recruiting
1,039 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡